{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:28:37Z","timestamp":1777566517091,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.bmcl.2020.127548","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T11:19:05Z","timestamp":1599909545000},"page":"127548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Discovery of 1-(1H-indazol-4-yl)-3-((1-phenyl-1H-pyrazol-5-yl)methyl) ureas as potent and thermoneutral TRPV1 antagonists"],"prefix":"10.1016","volume":"30","author":[{"given":"Jin Mi","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Ok","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihyae","family":"Ann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Blumberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heejin","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Dong","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Frank-Foltyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Lesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Bahrenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannelore","family":"Stockhausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7832-6719","authenticated-orcid":false,"given":"Jeewoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2020.127548_b0005","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0031-6997(24)01403-0","article-title":"Vanilloid (capsaicin) receptor and mechanism","volume":"51","author":"Szallasi","year":"1999","journal-title":"Pharmacol Rev."},{"key":"10.1016\/j.bmcl.2020.127548_b0010","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/nrd3456","article-title":"Transient receptor potential channels as therapeutic targets","volume":"10","author":"Moran","year":"2011","journal-title":"Nat Rev Drug Dis."},{"key":"10.1016\/j.bmcl.2020.127548_b0015","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/med.21427","article-title":"Medicinal chemistry, pharmacology, and clinical implications of TRPV1 receptor antagonists","volume":"4","author":"Tabrizi","year":"2017","journal-title":"Med Res Rev."},{"key":"10.1016\/j.bmcl.2020.127548_h0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bcp.2009.02.014","article-title":"Analgesic potential of TRPV1 antagonists","volume":"78","author":"Kym","year":"2009","journal-title":"Biochem Pharmacol."},{"key":"10.1016\/j.bmcl.2020.127548_h0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.brainresrev.2008.12.006","article-title":"Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks","volume":"60","author":"Wong","year":"2009","journal-title":"Brain Res Rev."},{"key":"10.1016\/j.bmcl.2020.127548_h0030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.drudis.2008.11.005","article-title":"Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway","volume":"14","author":"Gunthorpe","year":"2009","journal-title":"Drug Discov Today."},{"key":"10.1016\/j.bmcl.2020.127548_h0035","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/17460440802681300","article-title":"Screening TRPV1 antagonists for the treatment of pain: lessons learned over a decade","volume":"4","author":"Lazar","year":"2009","journal-title":"Expert Opin Drug Discov."},{"key":"10.1016\/j.bmcl.2020.127548_h0040","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1517\/13543776.2010.497756","article-title":"Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature","volume":"20","author":"Voight","year":"2010","journal-title":"Expert Opin Ther Pat."},{"key":"10.1016\/j.bmcl.2020.127548_h0045","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.tips.2012.09.002","article-title":"Multisteric TRPV1 nocisensor: a target for analgesics","volume":"33","author":"Szolcs\u00e1nyi","year":"2012","journal-title":"Trends Pharmacol Sci."},{"key":"10.1016\/j.bmcl.2020.127548_h0050","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1517\/13543784.2012.704021","article-title":"Targeting TRPV1 for pain relief: limits, losers and laurels","volume":"21","author":"Szallasi","year":"2012","journal-title":"Expert Opin Investig Drugs."},{"key":"10.1016\/j.bmcl.2020.127548_h0055","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2174\/1574889808666131209124012","article-title":"Modulation of the TRPV1 channel: current clinical trials and recent patents with focus on neurological conditions","volume":"8","author":"De Petrocellis","year":"2013","journal-title":"Recent Pat CNS Drug Discov."},{"key":"10.1016\/j.bmcl.2020.127548_h0060","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1517\/13543776.2015.1008449","article-title":"Transient receptor potential vanilloid type 1 antagonists: a patent review (2011\u20132014)","volume":"25","author":"Lee","year":"2015","journal-title":"Expert Opin Ther Pat."},{"key":"10.1016\/j.bmcl.2020.127548_b0025","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/39807","article-title":"The capsaicin receptor: a heat-activated ion channel in the pain pathway","volume":"389","author":"Caterina","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2020.127548_b0030","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0896-6273(00)80564-4","article-title":"The cloned capsaicin receptor integrates multiple pain-producing stimuli","volume":"21","author":"Tominaga","year":"1998","journal-title":"Neuron"},{"key":"10.1016\/j.bmcl.2020.127548_b0035","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1113\/jphysiol.2013.251751","article-title":"The role of endogenous molecules in modulating pain through transient receptor potential vanilloid 1 (TRPV1)","volume":"591","author":"Morales-Lazaro","year":"2013","journal-title":"J Physiol."},{"key":"10.1016\/j.bmcl.2020.127548_b0040","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1523\/JNEUROSCI.5150-09.2010","article-title":"Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia","volume":"30","author":"Garami","year":"2010","journal-title":"J Neurosci."},{"key":"10.1016\/j.bmcl.2020.127548_b0045","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1124\/jpet.111.190314","article-title":"Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature","volume":"342","author":"Reilly","year":"2012","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.bmcl.2020.127548_b0050","doi-asserted-by":"crossref","first-page":"e13038","DOI":"10.1111\/apha.13038","article-title":"TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: compounds\u2019 pharmacological profiles, in vivo targets, thermoeffectors recruited and implication for drug development","volume":"223","author":"Garami","year":"2018","journal-title":"Acta Physiol."},{"key":"10.1016\/j.bmcl.2020.127548_b0055","doi-asserted-by":"crossref","first-page":"107474","DOI":"10.1016\/j.pharmthera.2020.107474","article-title":"Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: insights from mathematical modeling and meta-analysis","volume":"208","author":"Garami","year":"2020","journal-title":"Pharmacol Ther."},{"key":"10.1016\/j.bmcl.2020.127548_b0060","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1021\/jm701007g","article-title":"Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management","volume":"51","author":"Gomtsyan","year":"2008","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2020.127548_b0065","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/jpet.108.138511","article-title":"(R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neuron in vivo","volume":"326","author":"Surowy","year":"2008","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.bmcl.2020.127548_b0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pain.2008.11.004","article-title":"Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodent, but attenuates antagonist-induced hyperthermia","volume":"142","author":"Honore","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.bmcl.2020.127548_b0075","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1021\/jm00068a014","article-title":"Analogues of capsaicin with agonist activity as novel analgesic agents: structure-activity studies. 1. The aromatic \u201cA-region\u201d","volume":"36","author":"Walpole","year":"1993","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2020.127548_b0080","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1016\/j.bmcl.2017.08.020","article-title":"Pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists","volume":"27","author":"Lee","year":"2017","journal-title":"Bioorg Med Chem Lett."},{"key":"10.1016\/j.bmcl.2020.127548_b0085","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jlac.198019800611","article-title":"Durchf\u00fchrung der jacobsonschen indazolsynthese im eintopfverfahren","volume":"6","author":"R\u00fcchardt","year":"1980","journal-title":"Liebigs Ann Chem."},{"key":"10.1016\/j.bmcl.2020.127548_b0090","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.tet.2010.01.024","article-title":"Synthesis of a photoswitchable azobenzene-functionalized tris(indazol-1-yl) borate ligand and its ruthenium(II) cyclopentadienide complex","volume":"66","author":"De Rouville","year":"2010","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bmcl.2020.127548_b0095","unstructured":"Compound 51: 1-((3-(tert-Butyl)-1-(3-chloro-4-fluorophenyl)-1H-pyrazol-5-yl)methyl)-3-(1H-indazol-4-yl)urea. brown solid, mp = 107.5 \u2013 109.1 \u02daC; 1H NMR (300 MHz, DMSO-d6) \u03b4 13.00 (s, 1H), 8.74 (s, 1H), 7.78 (d, J = 6.9 Hz, 1H), 7.58-7.54 (m, 4H), 7.19 (t, J = 7.8 Hz, 1H), 7.05 (d, J = 8.0 Hz, 1H), 6.79 (s, 1H), 6.36 (s, 1H), 4.43 (d, J = 5.8 Hz, 2H), 1.27 (s, 9H); HRMS (FAB) calc. for C22H23ClFN6O [M+H]+ 441.1528, found 441.1606."},{"key":"10.1016\/j.bmcl.2020.127548_b0100","doi-asserted-by":"crossref","first-page":"8392","DOI":"10.1021\/jm300780p","article-title":"2-(3-Fluoro-4-methylsulfonylaminophenyl) propanamides as potent transient receptor potential vanilloid 1 (TRPV1) antagonists: Structure activity relationships of 2-amino derivatives in the N-(6-trifluoromethyl-pyridin-3-ylmethyl) C-region","volume":"55","author":"Kim","year":"2012","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2020.127548_b0105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0304-3959(92)90003-T","article-title":"The formalin test: an evaluation of the method","volume":"51","author":"Tj\u00f8lsen","year":"1992","journal-title":"Pain"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X20306594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X20306594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:39:18Z","timestamp":1760773158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X20306594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":29,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0960894X20306594"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2020.127548","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of 1-(1H-indazol-4-yl)-3-((1-phenyl-1H-pyrazol-5-yl)methyl) ureas as potent and thermoneutral TRPV1 antagonists","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2020.127548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"127548"}}